CODEN [USA]: IAJPBB ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

http://doi.org/10.5281/zenodo.1305330

Available online at: http://www.iajps.com *Review Article*

HEPATITIS C VIRUS PREVELANCE AND MANAGEMENT IN PAKISTAN

Naeema Anwar[1], Sahrish Khan[1], Mehwish Durrani[1], Malala Ubaidullah[1], Samreen Basher[1], Binish Baig[2], Ehsan Ayoub[2], Fozia Karam Khan[1], and Sheikh Ahmed[1].

1 Institute of Biochemistry, University of Balochistan Quetta, Pakistan

2 Department of Microbiology, University of Balochistan, Quetta, Pakistan.

Abstract:

Hepatitis C virus the most serious problem in the world which is small RNA enveloped virus among the family Flaviridae including six genotypes which leads hepatocellular carcinoma (HCC),liver cirrhosis and cause of liver transplantation internationally. It is estimated that 170 million people have chronic HCV each year. In Pakistan around 10 million (5.9%) persons are purposed to stain with HCV among all six genotypes, genotype 3a is most prevalent in Pakistan by the ratio of 76.88% in Sindh 68.94% in Punjab, 60.71% in Balochistan and 58% in KPK. Misuse of injections has highlighted as the largest part dangerous factor for HCV infection. From Pakistan currently it's estimated have systematically calculated 500,000 chronic heroin users nationwide, have an ample amount of drug users that they use their drug course preferences as of noon insert able shapes to introduction utilize of so-called drugs from the last two years. Therapy of chronic HCV SVR rates improved to roughly 60% with pegylated IFN (PegIFN) and ribavirin (RBV) combination treatment, Majority of researches from Pakistan represent SVR and ETR with inexperienced victims by chronic hepatitis C after 6 months treatment with-alfa 2b triple times in a week and 800-1200 mg/day rate of ribavirin among 78.85%-88%, and 85.14%- 94% correspondingly. The HCV outbreak in Pakistan progress because of deficiency of awareness and education of the illness lack of medically trained and scientifically taught health care activators and deficiency of health communications.

Key Words: *Seroprevalence, Hepatitis C virus, Ribavirin (RBV), Pegylated IFN (PegIFN)*

Corresponding author:

Naeema Anwar,

Institute of Bio-Chemistry,
University of Balochistan,
Quetta, Pakistan

QR code

Please cite this article in press Naeema Anwar et al., ***Hepatitis C Virus Prevelance and Management in Pakistan,*** *Indo Am. J. P. Sci, 2018; 05(06).*

INTRODUCTION:

Hepatitis C virus (HCV) disease is one of the most serious diseases in all over the world. Acute HCV is mostly asymptomatic which promotes to chronic hepatitis and could be a main issue of mortality and morbidity [1-4]. HCV causes a progressed chronic form of the situation in doubtable patient[5]HCV is a small encircled RNA virus which has been to be paid to a specific genus, identified Hepacivirus, within the family Flaviridae[6-9].

HCV is the main known source including hepatic cirrhosis, hepatocellular carcinoma and fatal hepatic diseases. Victims of HCV are mostly symptomless and not educate about their sickness till ruthless and not reversible hepatic disease present [10, 11]. HCV antibodies are usually presence identification of HCV infection[12].

HCV can guide to hepatocellular carcinoma (HCC), hepatic fibrosis and is the leading cause of hepatic transplantation internationally[13].Viral RNA can be marked in serum in about 60-80% of HCV affected patients, telling constant infection; However, there is a large ratio of persons who are HCV antibody positive who have no spot of viral RNA in their serum[14].A defensive vaccine should wish to bring extensive responsive immunity for the proper handling of broad genomic assortment of HCV[15].

Viral and mass peptidases slash the large open reading frame, as a result in three systemic proteins (core ,envelope 1 , 2) a short protein known as nonstructural protein (NS) p6 and seven and proteins are (NS5A,A ,NS4A,B ,NS3, NS2).

At the 5 end of 324-341 nucleotides there is not coding section having the interior ribosome entrance site and a3 non coding section of different length that as well has a vital function in the duplication procedure [16, 17].

HCV shows a huge amount of genetic diversity and based on series examination, can be arranged into 6 main genotypes (selected 1 to 6) with greater than 100 subtypes (selected a, b, c and accordingly) [18].Mostly on world wide the only analytic test is anti-HCV ELISA , for the beginning finding which is costless for the long-ago time or resolute issues[19].

HCV genome

HCV is an aspheric, encircled Hepacivirus genus from the family Flaviviridae[20]. The virus having RNA genome around 9400 BP in extant is called HCV. Mostly an ORF is made by genome that instructs seven non-structural protein (p7, NS2, NS5B) and three formational (core, E1, E2) (Simmons, 2004) which have been cleaned by viroporin p7 from the NS proteins. The protein which has NS3 serine protease and NS2-3 auto protease is NS, an NTPase which is located in the NS5B RNA-reliant RNA, NS4A cofactor o NS3, the C-terminal 2/3rd of NS3 and multimerase the NS4B and NS5A proteins[21].E1 and E2 are formed following cleavage by a peptidase (SP) while maturation of core needs proteolysis by SP and a peptide peptidase(SPP) [22].



Fig.1 Structure of HCV [23]

The organization of HCV genome, polyprotein giving out and p7 predecessors. A chart image of the genome of HCV RNA which have the non-translated regions (NTR) on the 51 and 31 ends and the region

which codes is exposed on the top. The initiation codon is AUG and the stop codon is UGA that indicate the log reading frame, correspondingly. The polyprotein ancestor produced by IRES-dependent RNA translation and partitioned elements are mentioned beneath. Figures refers to amino acid existence of the JFH-1 separate (GenBank succession number AB047639). The multi-protein establisher bring on RNA translation by IRES-needy and No shape proteins are depicted p7 in blond, pink color and green in structural proteins[9].Of the genome, 5,UTR the majority extremely preserved area and hence has used is warmly laboratory to expend serious finding assay for the HCV RNA[24]. The life-cycle of HCV starts having a connection of an infection of virion with precise receiver on liver cells. Recently, the huge-mass scavenger receiver and lipoprotein receiver type B class, stuff joint protein claudin-1, tetraspanin CD81 and occluding are named as cellular receiver starting the joint stairs of HCV contamination (Li and Lo, 2015).
Genome duplication profits are in two ways combination of genomic RNA with this minus-thread RNA stencil and fusion of balancing minus-thread RNA with the genome as shape.

The input enzyme which was having all of these stairs is fixed (RdRp) the protein HCV NS5B, located at the polyprotein severe C terminus containing designs mutated from all Rp and Rds, as motif GDD[25].

Epidemiologic features
Concerning Hepatitis C virus, 170 million community have chronic infection and 3.5 to 4 million fresh infection happen annually, it has been projected [26].

The information's represented by world health origination (WHO) expected that more than one million fresh conditions were define annually and circumstance of HCV infection is 2.2% [16, 27].

Additionally, about 3-4 million persons are recognized as fresh issues per annual[26, 28].In all over the world it has been expected that the occurrence of anti-HCV consequent to 115 million (92-149), and to be 1.6% (2.1-1.3%) past viremic illness [29-33]. World Health information 2008 lists that liver cirrhosis like the 18th ordinary reason of mortality in the globe, and it is expected that by 2030,hepatic cancer will turn into the 13th general basis[34].

The quiet epidemic of chronic HCV infection is scattering fast in our country[35]. In Pakistan around 10 million (5.9%) people are purposed to tainted with HCV[36].

The positivity of HCV antibody is a huge threat collections (as hemophilia thalassemia patients and chronic hemodialysis patients or health heed team[37].

3a genotype of HCV has been initiated to have the major cause of infection in Pakistan however still there is lack of data to share the HCV genotypes and load of virus in diverse geological areas of Pakistan[34, 38]. HCV genotypes are not suggested in HCV tainted tolerant on day by day basis by the communities of Pakistani gastroenterology, because in Pakistan genotype three is present in a huge number [39].

A short learn was represented in 1997 that in Pakistan 87% persons were having genotype 3.A group of gastroenterologists which was the top 30 of the state assembled with a symposium in 2004 and presented the patients of HCV were 75-90% having genotype 3 in Pakistan [40].

This process presented that in Pakistan the ratio of infection of HCV in the patients of hepatitis are mostly qualified to genotype three, the ratio according to region wise, 68.94% in Punjab 76.88% in Sindh, 58% in KPK and 60.71% in Balochistan.
Additionally, the huge occurrence of genotype one less infected showed very close after first common genotype between examined inhabitants in Balochistan (32.14%), in KPK (20.16%), and in Sindh (8.33%) whereas in Punjab (12.14%)[24].

A previous considered represented that 8.9% of people is infected with HCV in Mardan [41]. However, enormous arrival of refugees from Afghanistan and (due to being on the border of Afghanistan) the geographic site of Quetta donated a great infection of HCV [42].The HCV outbreak in Pakistan progress because of lack of awareness and education of the illness lack of medically trained and scientifically taught health care activators and shortage of health communications [43].

Antiviral treatment
In history, the drug for HCV treatment has dependent on the interferon (administer by the injection) with ribavirin combination and is connected with relentless adverse effects[8, 44-46]. Since from the previous two years the infected tolerant by chronic HCV SVR rates have improved roughly 60% with (RBV) ribavirin and (PegIFN) pegylated IFN mixture of therapy [47, 48] [49].

Furthermore, the anti-HCV interferon therapy is not perfect due to this it needs dose on weekly bases and also combined having various side effects (*e.g.,* flu-like symptoms, fatigue, *etc.*).
Thus, next the treatment of anti-HCV is necessary [50].Peginterferon/ribavirin association treatment is optional for patients with HCV infection. Before therapy virological variations the existence of genotype 2 of HCV (HCV-2)or HCV-3 infection is the greatest predicator of continued virological response[51]. A lot of going therapies have been formed during last 10 years having specialization of genetic mixture with HCV, progressing of therapy having interferon of alpha and antibody of 3rd generation indicative trail in the majority of good clinical awareness.

Current time, most of the clinical laboratories on world level for the diagnostic is only anti-HCV ELISA test[19].As a result, this therapy routine results in sustained virological response (SVR)[52].The rates of SVR in this population improve to 75% either 66% or while telaprevir or boceprevir or telaprevir correspondingly, is unite to the routine.8 to 12 reaction rate are inclined by genotype and load of virus and by patient genetics, demographics and illness history [53].

The Therapy selection for chronic hepatitis C (CHC) is ribavirin and pegylated interferon-alpha (IFNa) for also 24 or 48 weeks depend on genotype [54].The recent standard care of treatment for the HCV genotypes 4,5 and 6 is pegylated interferon and ribavirin for 48 weeks. A small way of 24 weeks treatment perhaps measured with genotype 6 for patients [55].

As a result, patients with HCV infection are treated on the bases of quantitative or qualitative virus detection and genotypes are not examined prior to therapy in Pakistan. On the other hand various reaction rates of HCV tainted patients to antiviral treatment may not be diagnosed [56].

In most areas carry out has stayed less, instead of the interferon betterment having regimen, annually the treatment of chronic HCV starting with people ranging <1% at least 5% [57].

Examined from Pakistan majority of them represented SVR and ETR with inexperienced tolerant having CHC after the treatment of six month ,with-alfa 2b 3 MIU weekly thrice and daily 800-1200 mg ribavirin between the rate of 78.85%-88%, and 85.14%- 94% correspondingly.77-79 the respond ranges which are much to compare to SVR resulted next to ribavirin and the comparable genotype one (35%) or treatment of PEG-INF[58].

Interferon treatment is connected with amount of side effects such as gastrointestinal, thyroid functionless, neuropsychiatric side effects, hematological turmoil and way effects. In a couple of patients it was determined that clubbing of fingers and side effects of seizers are remarkable [59].

Risk factors
It has been clearly diagnosed that contact to infectious blood is the major risk spot for HCV infection[60, 61].1.5 million units of blood supplies transferred every each in Pakistan[62].Instead the extensive introduction of syringe and needle program since 1980s, HCV conduction progress at a huge level with recently injecting medicine users[63].

Methods closed to good therapy (barbershop shaving, pedicures, manicures, piercing and tattooing) can pose a necessary risk for virus conduction[64].An experienced 40000 children are made HCV positive women annually. mother to offspring conduction is the major way of infancy[65].

Mode of Transmission
Blood transfusions have been an important reason of (HCV) hepatitis C virus[66].In Pakistan there is likely of 10 t0 15 lack units of blood products transfused every year [62]. In Pakistan it is highlighted that mistreat of injections is a dangerous issue for HCV contamination [37].The issues that were gain at the rehabilitation centers via most surgery and using of syringes again and again is just about 70%, that is totally ordinary [67].

From Pakistan it is currently estimated that have systematically calculated 500,000 chronic heroin users nationwide, have an ample amount of drug addicts that use their drug on course choice from non insert able shapes to introduction use of synthesized drugs[68]. Most of the paramedics are not taught so and are unknown of leveled sterilization manner or the meaningful of safe inoculation practices in Pakistan[69].Shave and daily facial shave has been known as dangerous spots for HCV in Pakistan too[70].

Families with small socio-economic position and HCV associate having an improved HCV infection risk. Sharing of different domestic connections as nail clippers, razor blades and tooth brushes are dangerous spots for transmission of HCV [71].

Sexually transfer of Hepatitis C virus between heterosexual monogamous partners is an most effected event. The most occurrence rate of HCV conduction by sex was 0.07% per annum or about each year 190,000 sexual relation and the utmost occurrence of HCV infection between sexual couples of subjects have chronic HCV infection was just 1.2% [72].

Several clinical manners those are expecting the probable bases of HCV conduction, such as , endoscopy , sclerotherapy, invasive urologic procedures and hemodialysis, due to lack of clear-out of instruments or by the use vials multidose drugs and anesthetic are dangerous spot or infection source, indicating chance of nosocomial[60].
Hepatitis C virus conduction, HCV avoidance and progressing vaccine is not present, as a vaccine looks unbelievable in upcoming time. However, dining the possible bases of conduction and eliminating them is just a good way to decrease HCV infection[73].

CONCLUSIONS:

Hepatitis is the most dangerous in the world wide it needs serious action to control about a ten million group of people. Around 6% entire in Pakistan the people are being offended by contamination of HCV. Basically in Pakistan there is no suitable awareness to aware the people regarding the endemic diseases, there are programs started for the diseases prevention but also there is need of usual awareness workshops in district level and capital hospitals as the elevated ratio of occurrence beside the backward patients that get haemodialysis or got blood transfusion prior to the coming of equipments of diagnostic HCV as more long-sufferers are not informed about the assault of HCV diseases, since HCV has no acute phase so early apprehension of dedicated are having a particular arrangement to help out and recognize , advises, observations and care of patient. A threat of infection of HCV having it's connected complication and contamination. Constant education by initial concern physician and patient of the spot that increase the HCV conduction and virus succession might condense weigh down of syndrome and recognize many patients who could get the advantages from efficient analysis. as latest treatments available are most effective on all types of genotype but also need to be bothered.

REFERENCES:

1. Mengal, M.A., et al., *Seroprevalence of Hepatitis C Virus in General Population of Balochistan, Pakistan.* Pak J Med Health Sci, 2013. **7**(1): p. 180-4.
2. Osinusi, A., et al., *Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.* Jama, 2013. **310**(8): p. 804-811.
3. Lavanchy, D., *The global burden of hepatitis C.* Liver International, 2009. **29**(s1): p. 74-81.
4. Liakina, V., et al., *Historical epidemiology of hepatitis C virus (HCV) in select countries–volume 3.* Journal of viral hepatitis, 2015. **22**(S4): p. 4-20.
5. Khan, T.M., et al., *Frequency of hepatitis C virus genotypes in the north of Pakistan.* Gomal Journal of Medical Sciences, 2014. **12**(2).
6. Thomson, B. and R. Finch, *Hepatitis C virus infection.* Clinical Microbiology and Infection, 2005. **11**(2): p. 86-94.
7. Dubuisson, J. and F.-L. Cosset, *Virology and cell biology of the hepatitis C virus life cycle–An update.* Journal of hepatology, 2014. **61**(1): p. S3-S13.
8. Antonelli, A., et al., *Hepatitis C virus infection.* Diabetes Care, 2005. **28**(10): p. 2548-2550.
9. Madan, V. and R. Bartenschlager, *Structural and functional properties of the hepatitis C virus p7 viroporin.* Viruses, 2015. **7**(8): p. 4461-4481.
10. Lee, M.-H., et al., *Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study.* The Journal of Infectious Diseases, 2012. **206**(4): p. 469-477.
11. Lee, M.-H., et al., *Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study.* The Journal of Infectious Diseases, 2012. **206**(4): p. 469-477.
12. Mohd Hanafiah, K., et al., *Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence.* Hepatology, 2013. **57**(4): p. 1333-1342.
13. Chak, E., et al., *Hepatitis C virus infection in USA: an estimate of true prevalence.* Liver International, 2011. **31**(8): p. 1090-1101.
14. Afzal, M.S., et al., *Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan.* The Journal of Infection in Developing Countries, 2011. **5**(06): p. 473-479.
15. Cuypers, L., et al., *Genetic diversity and selective pressure in hepatitis C virus genotypes 1–6: significance for direct-acting antiviral treatment and drug resistance.* Viruses, 2015. **7**(9): p. 5018-5039.
16. Susser, S., et al., *Characterization of resistance to the protease inhibitor boceprevir in hepatitis*

C virus–infected patients. Hepatology, 2009. **50**(6): p. 1709-1718.
17. Paul, D., V. Madan, and R. Bartenschlager, *Hepatitis C virus RNA replication and assembly: living on the fat of the land.* Cell host & microbe, 2014. **16**(5): p. 569-579.
18. Tomei, L., et al., *Review HCV Antiviral Resistance: The Impact of in vitro Studies on the Development of Antiviral Agents Targeting the Viral NS5B Polymerase.* Antiviral chemistry and chemotherapy, 2005. **16**(4): p. 225-245.
19. Ahmad, N., et al., *An evidence of high prevalence of Hepatitis C virus in Faisalabad, Pakistan.* Saudi medical journal, 2007. **28**(3): p. 390.
20. Ramia, S. and J. Eid-Fares, *Distribution of hepatitis C virus genotypes in the Middle East.* International journal of infectious diseases, 2006. **10**(4): p. 272-277.
21. Boulant, S., et al., *Hepatitis C virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features.* Journal of virology, 2005. **79**(17): p. 11353-11365.
22. Boulant, S., et al., *Structural determinants that target the hepatitis C virus core protein to lipid droplets.* Journal of Biological Chemistry, 2006. **281**(31): p. 22236-22247.
23. Hussain, A., et al., *The Molecular Architecture of HCV: A review.* Journal of Applied and Emerging Sciences, 2013. **4**(1): p. pp75-85.
24. Attaullah, S., S. Khan, and I. Ali, *Hepatitis C virus genotypes in Pakistan: a systemic review.* Virology journal, 2011. **8**(1): p. 433.
25. Bressanelli, S., et al., *Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus.* Proceedings of the National Academy of Sciences, 1999. **96**(23): p. 13034-13039.
26. Rantala, M. and M. Van de Laar, *Surveillance and epidemiology of hepatitis B and C in Europe–a review.* Eurosurveillance, 2008. **13**(21): p. 18880.
27. Daw, M.A. and A.A. Dau, *Hepatitis C virus in Arab world: a state of concern.* The Scientific World Journal, 2012. **2012**.
28. Anwar, M.I., et al., *Prevalence of active hepatitis C virus infections among general public of Lahore, Pakistan.* Virology journal, 2013. **10**(1): p. 351.
29. Gower, E., et al., *Global epidemiology and genotype distribution of the hepatitis C virus infection.* Journal of hepatology, 2014. **61**(1): p. S45-S57.
30. Ampuero, J., M. Romero-Gómez, and K. Reddy, *HCV genotype 3–the new treatment challenge.* Alimentary pharmacology & therapeutics, 2014. **39**(7): p. 686-698.
31. Shaheen, A.A.M. and R.P. Myers, *Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C–related fibrosis: A systematic review.* Hepatology, 2007. **46**(3): p. 912-921.
32. Tawar, R.G., et al., *Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.* Hepatology, 2015. **62**(3): p. 726-736.
33. Negro, F. and A. Alberti, *The global health burden of hepatitis C virus infection.* Liver International, 2011. **31**(s2): p. 1-3.
34. Umar, M., et al., *Hepatitis C in Pakistan: a review of available data.* Hepatitis monthly, 2010. **10**(3): p. 205.
35. Ejaz, A., et al., *Frequency of various cutaneous disorders in chronic hepatitis C virus infection.* Journal of Pakistan Association of Dermatology, 2016. **20**(1): p. 10-14.
36. Lavanchy, D., *Evolving epidemiology of hepatitis C virus.* Clinical Microbiology and Infection, 2011. **17**(2): p. 107-115.
37. Umar, M. and M. Bilal, *Hepatitis C, a mega menace: a Pakistani Perspective.* Journal of Pioneering Medical Sciences, 2012. **2**(2): p. 68.
38. Afridi, S.Q., et al., *Molecular epidemiology and viral load of HCV in different regions of Punjab, Pakistan.* Virology journal, 2014. **11**(1): p. 24.
39. Ijaz, B., et al., *Association of laboratory parameters with viral factors in patients with hepatitis C.* Virology journal, 2011. **8**(1): p. 361.
40. Waheed, Y., et al., *Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors.* World journal of gastroenterology: WJG, 2009. **15**(45): p. 5647.
41. Ali, S., et al., *Genotyping of HCV RNA reveals that 3a is the most prevalent genotype in mardan, pakistan.* Advances in virology, 2014. **2014**.
42. Khan, A., et al., *Prevalence of HCV among the young male blood donors of Quetta region of Balochistan, Pakistan.* Virology journal, 2013. **10**(1): p. 83.
43. Raja, N.S. and K.A. Janjua, *Epidemiology of hepatitis C virus infection in Pakistan.* Journal of Microbiology Immunology and Infection, 2008. **41**(1): p. 4.
44. Messina, J.P., et al., *Global distribution and prevalence of hepatitis C virus genotypes.* Hepatology, 2015. **61**(1): p. 77-87.
45. Moyer, V.A., *Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation statement.* Annals of internal medicine, 2013. **159**(5): p. 349-357.

46. Thomas, E., et al., *Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models.* Hepatology, 2011. **53**(1): p. 32-41.
47. van der Meer, A., *Antiviral Therapy for Chronic HCV Infection: Virological Response and Long-Term Outcome*. 2014.
48. Simmons, B., et al., *Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response.* Clinical Infectious Diseases, 2015. **61**(5): p. 730-740.
49. Yoshida, E.M., et al., *Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.* Hepatology, 2015. **61**(1): p. 41-45.
50. Li, H.-C. and S.-Y. Lo, *Hepatitis C virus: Virology, diagnosis and treatment.* World journal of hepatology, 2015. **7**(10): p. 1377.
51. Yu, M.L., et al., *Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.* Hepatology, 2011. **53**(1): p. 7-13.
52. Muir, A.J., et al., *Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.* Hepatology, 2010. **52**(3): p. 822-832.
53. Chayama, K., et al., *Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders.* Hepatology, 2012. **55**(3): p. 742-748.
54. Sockalingam, S., P. Links, and S. Abbey, *Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update*. Journal of viral hepatitis, 2011. **18**(3): p. 153-160.
55. Wantuck, J., A. Ahmed, and M. Nguyen, *the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6.* Alimentary pharmacology & therapeutics, 2014. **39**(2): p. 137-147.
56. Saleha, S., et al., *Prevalence of hepatitis C virus genotypes in district bannu, khyber pakhtunkhwa, pakistan.* Hepatitis research and treatment, 2014. **2014**.
57. Dore, G.J. and J.J. Feld, *Hepatitis C virus therapeutic development: in pursuit of "perfectovir".* Clinical Infectious Diseases, 2015. **60**(12): p. 1829-1836.
58. Jafri, W. and A. Subhan, *Hepatitis C in Pakistan: Magnitude, Genotype, Disease Characteristics and Therapeutic*. Tropical Gastroenterology, 2008. **4**: p. 194-201.
59. Waheed, Y., *Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: Treatment response, side effects and future prospective.* Asian Pacific journal of tropical medicine, 2015. **8**(2): p. 85-89.
60. de Almeida Pondé, R.A., *Hidden hazards of HCV transmission.* Medical microbiology and immunology, 2011. **200**(1): p. 7-11.
61. Tuaillon, E., et al., *Dried blood spot for hepatitis C virus serology and molecular testing.* Hepatology, 2010. **51**(3): p. 752-758.
62. Ali, S.A., et al., *Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors.* International journal of infectious diseases, 2009. **13**(1): p. 9-19.
63. Omata, M., et al., *Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.* Hepatology international, 2015. **9**(4): p. 486-507.
64. Villar, L.M., et al., *Knowledge and prevalence of viral hepatitis among beauticians.* Journal of medical virology, 2014. **86**(9): p. 1515-1521.
65. Cottrell, E.B., et al., *Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the US Preventive Services Task Force.* Annals of internal medicine, 2013. **158**(2): p. 109-113.
66. Oh, D.J., et al., *Prevalence of hepatitis C virus infections and distribution of hepatitis C virus genotypes among Korean blood donors.* Annals of laboratory medicine, 2012. **32**(3): p. 210-215.
67. Akbar, H., et al., *Hepatitis C virus infection: A review of the current and future aspects and concerns in Pakistan.* Journal of General and Molecular Virology, 2009. **1**(2): p. 012-018.
68. Emmanuel, F. and A. Attarad, *Correlates of injection use of synthetic drugs among drug users in Pakistan: a case controlled study.* Journal-Pakistan Medical Association, 2006. **56**(3): p. 119.
69. GHAFFAR, N., et al., *ASSESSMENT OF RISK FACTORS FOR HEPATITIS C IN REPRODUCTIVE LIFE OF WOMEN: A TERTIARY CARE HOSPITAL BASED STUDY FROM QUETTA, BALOCHISTAN-PAKISTAN.* Biomedica, 2015. **31**(2).
70. Janjua, N. and M. Nizamy, *Knowledge and practices of barbers about hepatitis B and C transmission in Rawalpindi and Islamabad.* Journal-Pakistan Medical Association, 2004. **54**(3): p. 116-118.
71. Bari, A., et al., *Risk factors for hepatitis C virus infection in male adults in Rawalpindi–*

Islamabad, Pakistan. Tropical medicine & international health, 2001. **6**(9): p. 732-738.
72. Terrault, N.A., et al., *Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study.* Hepatology, 2013. **57**(3): p. 881-889.
73. Mahboobi, N., et al., *Dental treatment as a risk factor for hepatitis B and C viral infection. A review of the recent literature*. J Gastrointestin Liver Dis, 2013. **22**(1): p. 79-86.